54 related articles for article (PubMed ID: 36017142)
21. TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast Cancer.
Jiang Y; Liu Y; Tan X; Yu S; Luo J
Clin Breast Cancer; 2019 Dec; 19(6):450-455. PubMed ID: 31494045
[TBL] [Abstract][Full Text] [Related]
22. Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population.
Hashmi AA; Naz S; Hashmi SK; Hussain ZF; Irfan M; Bakar SMA; Faridi N; Khan A; Edhi MM
BMC Res Notes; 2018 Jun; 11(1):372. PubMed ID: 29884220
[TBL] [Abstract][Full Text] [Related]
23. Wnt7a Deficiency Could Predict Worse Disease-Free and Overall Survival in Estrogen Receptor-Positive Breast Cancer.
Yi K; Min KW; Wi YC; Kim Y; Shin SJ; Chung MS; Jang K; Paik SS
J Breast Cancer; 2017 Dec; 20(4):361-367. PubMed ID: 29285041
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.
Krishnamurthy N; Kurzrock R
Cancer Treat Rev; 2018 Jan; 62():50-60. PubMed ID: 29169144
[TBL] [Abstract][Full Text] [Related]
25. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.
Chandrashekar DS; Bashel B; Balasubramanya SAH; Creighton CJ; Ponce-Rodriguez I; Chakravarthi BVSK; Varambally S
Neoplasia; 2017 Aug; 19(8):649-658. PubMed ID: 28732212
[TBL] [Abstract][Full Text] [Related]
26. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.
Tang Z; Li C; Kang B; Gao G; Li C; Zhang Z
Nucleic Acids Res; 2017 Jul; 45(W1):W98-W102. PubMed ID: 28407145
[TBL] [Abstract][Full Text] [Related]
27. FRAT1 expression regulates proliferation in colon cancer cells.
Zhu K; Guo J; Wang H; Yu W
Oncol Lett; 2016 Dec; 12(6):4761-4766. PubMed ID: 28101222
[TBL] [Abstract][Full Text] [Related]
28. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Bianchini G; Balko JM; Mayer IA; Sanders ME; Gianni L
Nat Rev Clin Oncol; 2016 Nov; 13(11):674-690. PubMed ID: 27184417
[TBL] [Abstract][Full Text] [Related]
29. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.
Tomczak K; Czerwińska P; Wiznerowicz M
Contemp Oncol (Pozn); 2015; 19(1A):A68-77. PubMed ID: 25691825
[TBL] [Abstract][Full Text] [Related]
30. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
31. Expression of Frat1 correlates with expression of β-catenin and is associated with a poor clinical outcome in human SCC and AC.
Zhang Y; Han Y; Zheng R; Yu JH; Miao Y; Wang L; Wang EH
Tumour Biol; 2012 Oct; 33(5):1437-44. PubMed ID: 22528942
[TBL] [Abstract][Full Text] [Related]
32. Dissecting the heterogeneity of triple-negative breast cancer.
Metzger-Filho O; Tutt A; de Azambuja E; Saini KS; Viale G; Loi S; Bradbury I; Bliss JM; Azim HA; Ellis P; Di Leo A; Baselga J; Sotiriou C; Piccart-Gebhart M
J Clin Oncol; 2012 May; 30(15):1879-87. PubMed ID: 22454417
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity in breast cancer.
Polyak K
J Clin Invest; 2011 Oct; 121(10):3786-8. PubMed ID: 21965334
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer.
Zhang Y; Yu JH; Lin XY; Miao Y; Han Y; Fan CF; Dong XJ; Dai SD; Wang EH
Virchows Arch; 2011 Sep; 459(3):255-63. PubMed ID: 21818639
[TBL] [Abstract][Full Text] [Related]
35. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer.
Jézéquel P; Campone M; Gouraud W; Guérin-Charbonnel C; Leux C; Ricolleau G; Campion L
Breast Cancer Res Treat; 2012 Feb; 131(3):765-75. PubMed ID: 21452023
[TBL] [Abstract][Full Text] [Related]
36. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.
Schnitt SJ
Mod Pathol; 2010 May; 23 Suppl 2():S60-4. PubMed ID: 20436504
[TBL] [Abstract][Full Text] [Related]
37. The expression profile of FRAT1 in human gliomas.
Guo G; Mao X; Wang P; Liu B; Zhang X; Jiang X; Zhong C; Huo J; Jin J; Zhuo Y
Brain Res; 2010 Mar; 1320():152-8. PubMed ID: 20096670
[TBL] [Abstract][Full Text] [Related]
38. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
Anders CK; Carey LA
Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S73-81. PubMed ID: 19596646
[TBL] [Abstract][Full Text] [Related]
39. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma.
Wang Y; Liu S; Zhu H; Zhang W; Zhang G; Zhou X; Zhou C; Quan L; Bai J; Xue L; Lu N; Xu N
Int J Cancer; 2008 Aug; 123(3):561-8. PubMed ID: 18498136
[TBL] [Abstract][Full Text] [Related]
40. FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A.
Hagen T; Cross DA; Culbert AA; West A; Frame S; Morrice N; Reith AD
J Biol Chem; 2006 Nov; 281(46):35021-9. PubMed ID: 16982607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
